Pharma Stock Roundup: FDA Approves SNY's Dupixent for COPD & More
FDA approves Sanofi's Dupixent for COPD. Eli Lilly is set to invest $4.5 billion to build a new manufacturing and research ...
Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...
Sanofi inks $1B deal to sell autoimmune disorder therapy
French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...
Chronic Urticaria Competitive Landscape Assessment 2024: Regeneron/Sanofi (Dupixent) and Genentech/Novartis (Xolair) Dominate the Market
The "Chronic Urticaria: Competitive Landscape" report has been added tAndMarkets.com's offering.This report provides a data-driven overview of the current and future competitive landscape in chronic ...